Recent advances in CAR-T cell engineeringRuihao Huang, Xi Zhang, Xiaoping Li et al.|Journal of Hematology & Oncology|2020Cited by 403
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Youngil Koh et al.|The Lancet Oncology|2023Cited by 55
Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical LeiomyomaQiu Bi, Yiqing Shen, Zhibo Xiao et al.|Academic Radiology|2018Cited by 33
Abstract CT052: Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)Xinxin Wang, Xi Zhang, Shiqi Li et al.|Cancer Research|2020Cited by 30
Synthesis of Multi-Stimuli Responsive Fe3O4 Coated with Diamonds Nanocomposite for Magnetic Assisted Chemo-Photothermal TherapyYang Li, Yao Liu, Jichuan Kong et al.|Molecules|2023Cited by 19